Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

A Randomized, Prospective Study of the Efficacy and Safety of the 1st Treatment in Advanced Central NSCLC by PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Bronchoscopic Microwave Intervention

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04360655

Enrollment

Registered

2020-04-24

Start date

2020-05-01

Completion date

2023-05-01

Last updated

2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect Increased, Safety Issues

Keywords

anti-PD-1 / PD-L1 monoclonal antibody, chemotherapy, bronchoscopic microwave intervention, advanced central non-small cell lung cancer patients

Brief summary

A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention

Detailed description

This study is a randomized, prospective study, which will analyze the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention. The efficacy will include objective response rate, disease control rate, progression-free survival, and overall survival. The safety will include adverse events and quality of life.

Interventions

PROCEDUREbronchoscopic microwave intervention

bronchoscopic microwave intervention

DRUGanti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* advanced central non-small cell lung cancer patients, untreated, tolerating bronchoscopy

Exclusion criteria

* contraindications to tracheoscopy, chemotherapy, and immunotherapy

Design outcomes

Primary

Measure	Time frame	Description
objective response rate	6 weeks	objective response rate
progression-free survival	1 years	progression-free survival

Secondary

Measure	Time frame	Description
adverse events	3 weeks	adverse events
disease control rate	6 weeks	disease control rate
overall survival	2 years	overall survival
quality of life score	World Health Organization Quality of Life Scale-Brief (WHOQOL-BREF)score 0-100，higher scores mean a better outcome.	quality of life score

Contacts

Primary ContactYayi He

doctorjael@foxmail.com862165115006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026